Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling
ABSTRACT Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases r...
Gespeichert in:
Veröffentlicht in: | Journal of bone and mineral research 2021-07, Vol.36 (7), p.1340-1350 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1350 |
---|---|
container_issue | 7 |
container_start_page | 1340 |
container_title | Journal of bone and mineral research |
container_volume | 36 |
creator | Kaufmann, Martin Schlingmann, Karl‐Peter Berezin, Linor Molin, Arnaud Sheftel, Jesse Vig, Melanie Gallagher, John C. Nagata, Akiko Masoud, Shadi Sedghi Sakamoto, Ryota Nagasawa, Kazuo Uesugi, Motonari Kottler, Marie Laure Konrad, Martin Jones, Glenville |
description | ABSTRACT
Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR). |
doi_str_mv | 10.1002/jbmr.4306 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03218618v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2513240951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</originalsourceid><addsrcrecordid>eNp10c1u1DAQB3ALgei2cOAFUCQu9JB2_LnOsR9AQYuQEJytWWfSeuUki50U7Y134A15EhK2tBISp5Gsn_6e0Z-xFxxOOIA43azbdKIkmEdswbWQpTKWP2YLsFaVoCQ_YIc5bwDAaGOesgMprTZLEAvWXIamoUTdEDAWdcDrrs8hF31T3IYB29AVl79-_EwUcaC6uNltKXmMntqAxZhDd11kSmP7oIuWBlz3MQxUbFPfhDihZ-xJgzHT87t5xL6-ffPl4qpcfXr3_uJsVXplrSkFERnha6MFqNoSWjJYIV8r1L72dSU9mkota8UlIkmSldceG9BLsJ5AHrHjfe4NRrdNocW0cz0Gd3W2cvMbSMGt4faWT_b13k5bfhspD64N2VOM2FE_Zic0l0JBpWf66h-66cfUTZdMSgsLlZH24XOf-pwTNfcbcHBzUW4uys1FTfblXeK4bqm-l3-bmcDpHnwPkXb_T3Ifzj9-_hP5G3-Knr4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552809638</pqid></control><display><type>article</type><title>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kaufmann, Martin ; Schlingmann, Karl‐Peter ; Berezin, Linor ; Molin, Arnaud ; Sheftel, Jesse ; Vig, Melanie ; Gallagher, John C. ; Nagata, Akiko ; Masoud, Shadi Sedghi ; Sakamoto, Ryota ; Nagasawa, Kazuo ; Uesugi, Motonari ; Kottler, Marie Laure ; Konrad, Martin ; Jones, Glenville</creator><creatorcontrib>Kaufmann, Martin ; Schlingmann, Karl‐Peter ; Berezin, Linor ; Molin, Arnaud ; Sheftel, Jesse ; Vig, Melanie ; Gallagher, John C. ; Nagata, Akiko ; Masoud, Shadi Sedghi ; Sakamoto, Ryota ; Nagasawa, Kazuo ; Uesugi, Motonari ; Kottler, Marie Laure ; Konrad, Martin ; Jones, Glenville</creatorcontrib><description>ABSTRACT
Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).</description><identifier>ISSN: 0884-0431</identifier><identifier>EISSN: 1523-4681</identifier><identifier>DOI: 10.1002/jbmr.4306</identifier><identifier>PMID: 33856702</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>1,24,25‐TRIHYDROXYVITAMIN D3 ; 23,25,26‐TRIHYDROXYVITAMIN D3 ; 24,25‐DIHYDROXYVITAMIN D ; 25-Hydroxyvitamin D ; 25‐HYDROXYVITAMIN D3‐26,23‐LACTONE ; Calcium ; Calcium (blood) ; CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS ; CYP24A1 ; Differential diagnosis ; DISEASES AND DISORDERS OF/RELATED TO BONE ; Genetic screening ; Hydroxylase ; HYPERCALCEMIA ; Hypervitaminosis ; LC‐MS/MS ; Life Sciences ; Liquid chromatography ; Mass spectroscopy ; Metabolites ; Mutation ; NUTRITION ; Nutritional status ; Patients ; PTH/Vit D/FGF23 ; SCREENING ; Sodium phosphate ; Vitamin D ; Williams syndrome</subject><ispartof>Journal of bone and mineral research, 2021-07, Vol.36 (7), p.1340-1350</ispartof><rights>2021 American Society for Bone and Mineral Research (ASBMR).</rights><rights>2021 American Society for Bone and Mineral Research</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</citedby><cites>FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</cites><orcidid>0000-0003-3192-9851 ; 0000-0001-7402-3473 ; 0000-0003-0163-2205 ; 0000-0003-0520-2800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjbmr.4306$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjbmr.4306$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33856702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://normandie-univ.hal.science/hal-03218618$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaufmann, Martin</creatorcontrib><creatorcontrib>Schlingmann, Karl‐Peter</creatorcontrib><creatorcontrib>Berezin, Linor</creatorcontrib><creatorcontrib>Molin, Arnaud</creatorcontrib><creatorcontrib>Sheftel, Jesse</creatorcontrib><creatorcontrib>Vig, Melanie</creatorcontrib><creatorcontrib>Gallagher, John C.</creatorcontrib><creatorcontrib>Nagata, Akiko</creatorcontrib><creatorcontrib>Masoud, Shadi Sedghi</creatorcontrib><creatorcontrib>Sakamoto, Ryota</creatorcontrib><creatorcontrib>Nagasawa, Kazuo</creatorcontrib><creatorcontrib>Uesugi, Motonari</creatorcontrib><creatorcontrib>Kottler, Marie Laure</creatorcontrib><creatorcontrib>Konrad, Martin</creatorcontrib><creatorcontrib>Jones, Glenville</creatorcontrib><title>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</title><title>Journal of bone and mineral research</title><addtitle>J Bone Miner Res</addtitle><description>ABSTRACT
Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).</description><subject>1,24,25‐TRIHYDROXYVITAMIN D3</subject><subject>23,25,26‐TRIHYDROXYVITAMIN D3</subject><subject>24,25‐DIHYDROXYVITAMIN D</subject><subject>25-Hydroxyvitamin D</subject><subject>25‐HYDROXYVITAMIN D3‐26,23‐LACTONE</subject><subject>Calcium</subject><subject>Calcium (blood)</subject><subject>CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS</subject><subject>CYP24A1</subject><subject>Differential diagnosis</subject><subject>DISEASES AND DISORDERS OF/RELATED TO BONE</subject><subject>Genetic screening</subject><subject>Hydroxylase</subject><subject>HYPERCALCEMIA</subject><subject>Hypervitaminosis</subject><subject>LC‐MS/MS</subject><subject>Life Sciences</subject><subject>Liquid chromatography</subject><subject>Mass spectroscopy</subject><subject>Metabolites</subject><subject>Mutation</subject><subject>NUTRITION</subject><subject>Nutritional status</subject><subject>Patients</subject><subject>PTH/Vit D/FGF23</subject><subject>SCREENING</subject><subject>Sodium phosphate</subject><subject>Vitamin D</subject><subject>Williams syndrome</subject><issn>0884-0431</issn><issn>1523-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10c1u1DAQB3ALgei2cOAFUCQu9JB2_LnOsR9AQYuQEJytWWfSeuUki50U7Y134A15EhK2tBISp5Gsn_6e0Z-xFxxOOIA43azbdKIkmEdswbWQpTKWP2YLsFaVoCQ_YIc5bwDAaGOesgMprTZLEAvWXIamoUTdEDAWdcDrrs8hF31T3IYB29AVl79-_EwUcaC6uNltKXmMntqAxZhDd11kSmP7oIuWBlz3MQxUbFPfhDihZ-xJgzHT87t5xL6-ffPl4qpcfXr3_uJsVXplrSkFERnha6MFqNoSWjJYIV8r1L72dSU9mkota8UlIkmSldceG9BLsJ5AHrHjfe4NRrdNocW0cz0Gd3W2cvMbSMGt4faWT_b13k5bfhspD64N2VOM2FE_Zic0l0JBpWf66h-66cfUTZdMSgsLlZH24XOf-pwTNfcbcHBzUW4uys1FTfblXeK4bqm-l3-bmcDpHnwPkXb_T3Ifzj9-_hP5G3-Knr4</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Kaufmann, Martin</creator><creator>Schlingmann, Karl‐Peter</creator><creator>Berezin, Linor</creator><creator>Molin, Arnaud</creator><creator>Sheftel, Jesse</creator><creator>Vig, Melanie</creator><creator>Gallagher, John C.</creator><creator>Nagata, Akiko</creator><creator>Masoud, Shadi Sedghi</creator><creator>Sakamoto, Ryota</creator><creator>Nagasawa, Kazuo</creator><creator>Uesugi, Motonari</creator><creator>Kottler, Marie Laure</creator><creator>Konrad, Martin</creator><creator>Jones, Glenville</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><general>American Society for Bone and Mineral Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TS</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-3192-9851</orcidid><orcidid>https://orcid.org/0000-0001-7402-3473</orcidid><orcidid>https://orcid.org/0000-0003-0163-2205</orcidid><orcidid>https://orcid.org/0000-0003-0520-2800</orcidid></search><sort><creationdate>202107</creationdate><title>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</title><author>Kaufmann, Martin ; Schlingmann, Karl‐Peter ; Berezin, Linor ; Molin, Arnaud ; Sheftel, Jesse ; Vig, Melanie ; Gallagher, John C. ; Nagata, Akiko ; Masoud, Shadi Sedghi ; Sakamoto, Ryota ; Nagasawa, Kazuo ; Uesugi, Motonari ; Kottler, Marie Laure ; Konrad, Martin ; Jones, Glenville</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4886-2eee62cd65204d8ea8e6a9a1b4a5cdcd93ca6947d413aae3e39c5caf05708ce03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>1,24,25‐TRIHYDROXYVITAMIN D3</topic><topic>23,25,26‐TRIHYDROXYVITAMIN D3</topic><topic>24,25‐DIHYDROXYVITAMIN D</topic><topic>25-Hydroxyvitamin D</topic><topic>25‐HYDROXYVITAMIN D3‐26,23‐LACTONE</topic><topic>Calcium</topic><topic>Calcium (blood)</topic><topic>CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS</topic><topic>CYP24A1</topic><topic>Differential diagnosis</topic><topic>DISEASES AND DISORDERS OF/RELATED TO BONE</topic><topic>Genetic screening</topic><topic>Hydroxylase</topic><topic>HYPERCALCEMIA</topic><topic>Hypervitaminosis</topic><topic>LC‐MS/MS</topic><topic>Life Sciences</topic><topic>Liquid chromatography</topic><topic>Mass spectroscopy</topic><topic>Metabolites</topic><topic>Mutation</topic><topic>NUTRITION</topic><topic>Nutritional status</topic><topic>Patients</topic><topic>PTH/Vit D/FGF23</topic><topic>SCREENING</topic><topic>Sodium phosphate</topic><topic>Vitamin D</topic><topic>Williams syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaufmann, Martin</creatorcontrib><creatorcontrib>Schlingmann, Karl‐Peter</creatorcontrib><creatorcontrib>Berezin, Linor</creatorcontrib><creatorcontrib>Molin, Arnaud</creatorcontrib><creatorcontrib>Sheftel, Jesse</creatorcontrib><creatorcontrib>Vig, Melanie</creatorcontrib><creatorcontrib>Gallagher, John C.</creatorcontrib><creatorcontrib>Nagata, Akiko</creatorcontrib><creatorcontrib>Masoud, Shadi Sedghi</creatorcontrib><creatorcontrib>Sakamoto, Ryota</creatorcontrib><creatorcontrib>Nagasawa, Kazuo</creatorcontrib><creatorcontrib>Uesugi, Motonari</creatorcontrib><creatorcontrib>Kottler, Marie Laure</creatorcontrib><creatorcontrib>Konrad, Martin</creatorcontrib><creatorcontrib>Jones, Glenville</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Physical Education Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of bone and mineral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaufmann, Martin</au><au>Schlingmann, Karl‐Peter</au><au>Berezin, Linor</au><au>Molin, Arnaud</au><au>Sheftel, Jesse</au><au>Vig, Melanie</au><au>Gallagher, John C.</au><au>Nagata, Akiko</au><au>Masoud, Shadi Sedghi</au><au>Sakamoto, Ryota</au><au>Nagasawa, Kazuo</au><au>Uesugi, Motonari</au><au>Kottler, Marie Laure</au><au>Konrad, Martin</au><au>Jones, Glenville</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling</atitle><jtitle>Journal of bone and mineral research</jtitle><addtitle>J Bone Miner Res</addtitle><date>2021-07</date><risdate>2021</risdate><volume>36</volume><issue>7</issue><spage>1340</spage><epage>1350</epage><pages>1340-1350</pages><issn>0884-0431</issn><eissn>1523-4681</eissn><abstract>ABSTRACT
Genetic causes of vitamin D–related hypercalcemia are known to involve mutation of 25‐hydroxyvitamin D‐24‐hydroxylase CYP24A1 or the sodium phosphate co‐transporter SLC34A1, which result in excessive 1,25‐(OH)2D hormonal action. However, at least 20% of idiopathic hypercalcemia (IH) cases remain unresolved. In this case‐control study, we used precision vitamin D metabolite profiling based on liquid chromatography–tandem mass spectrometry (LC‐MS/MS) of an expanded range of vitamin D metabolites to screen German and French cohorts of hypercalcemia patients, to identify patients with altered vitamin D metabolism where involvement of CYP24A1 or SLC34A1 mutation had been ruled out and who possessed normal 25‐OH‐D3:24,25‐(OH)2D3 ratios. Profiles were compared to those of hypercalcemia patients with hypervitaminosis D, Williams‐Beuren syndrome (WBS), CYP24A1 mutation, and normal subjects with a range of 25‐OH‐D levels. We observed that certain IH and WBS patients exhibited a unique profile comprising eightfold to 10‐fold higher serum 23,25,26‐(OH)3D3 and 25‐OH‐D3‐26,23‐lactone than normals, as well as very low serum 1,25‐(OH)2D3 (2–5 pg/ml) and elevated 1,24,25‐(OH)3D3, which we interpret implies hypersensitive expression of vitamin D–dependent genes, including CYP24A1, as a general underlying mechanism of hypercalcemia in these patients. Because serum 25‐OH‐D3 and 24,25‐(OH)2D3 remained normal, we excluded the possibility that the aberrant profile was caused by hypervitaminosis D, but instead points to an underlying genetic cause that parallels the effect of Williams syndrome transcription factor deficiency in WBS. Furthermore, we observed normalization of serum calcium and vitamin D metabolite profiles at follow‐up of an IH patient where 25‐OH‐D was reduced to 9 ng/ml, suggesting that symptomatic IH may depend on vitamin D nutritional status. Other hypercalcemic patients with complex conditions exhibited distinct vitamin D metabolite profiles. Our work points to the importance of serum vitamin D metabolite profiling in the differential diagnosis of vitamin D–related hypercalcemia that can rationalize expensive genetic testing, and assist healthcare providers in selecting appropriate treatment. © 2021 American Society for Bone and Mineral Research (ASBMR).</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>33856702</pmid><doi>10.1002/jbmr.4306</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-3192-9851</orcidid><orcidid>https://orcid.org/0000-0001-7402-3473</orcidid><orcidid>https://orcid.org/0000-0003-0163-2205</orcidid><orcidid>https://orcid.org/0000-0003-0520-2800</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0884-0431 |
ispartof | Journal of bone and mineral research, 2021-07, Vol.36 (7), p.1340-1350 |
issn | 0884-0431 1523-4681 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_03218618v1 |
source | Wiley Online Library Journals Frontfile Complete; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
subjects | 1,24,25‐TRIHYDROXYVITAMIN D3 23,25,26‐TRIHYDROXYVITAMIN D3 24,25‐DIHYDROXYVITAMIN D 25-Hydroxyvitamin D 25‐HYDROXYVITAMIN D3‐26,23‐LACTONE Calcium Calcium (blood) CELL/TISSUE SIGNALING–ENDOCRINE PATHWAYS CYP24A1 Differential diagnosis DISEASES AND DISORDERS OF/RELATED TO BONE Genetic screening Hydroxylase HYPERCALCEMIA Hypervitaminosis LC‐MS/MS Life Sciences Liquid chromatography Mass spectroscopy Metabolites Mutation NUTRITION Nutritional status Patients PTH/Vit D/FGF23 SCREENING Sodium phosphate Vitamin D Williams syndrome |
title | Differential diagnosis of vitamin D–related hypercalcemia using serum vitamin D metabolite profiling |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T13%3A16%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20diagnosis%20of%20vitamin%20D%E2%80%93related%20hypercalcemia%20using%20serum%20vitamin%20D%20metabolite%20profiling&rft.jtitle=Journal%20of%20bone%20and%20mineral%20research&rft.au=Kaufmann,%20Martin&rft.date=2021-07&rft.volume=36&rft.issue=7&rft.spage=1340&rft.epage=1350&rft.pages=1340-1350&rft.issn=0884-0431&rft.eissn=1523-4681&rft_id=info:doi/10.1002/jbmr.4306&rft_dat=%3Cproquest_hal_p%3E2513240951%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552809638&rft_id=info:pmid/33856702&rfr_iscdi=true |